Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2012 by University of Washington.
Recruitment status was  Active, not recruiting
Alzheimer's Association
Information provided by (Responsible Party):
Suzanne Craft, University of Washington Identifier:
First received: May 8, 2012
Last updated: December 17, 2012
Last verified: December 2012

The study will examine the effects of intranasally administered long-acting insulin detemir on cognition in persons with Alzheimer's disease (AD) or amnestic mild cognitive impairment (aMCI). The rationale for these studies is derived from growing evidence that insulin contributes to multiple brain functions, and that insulin dysregulation can contribute to AD pathogenesis. Thus, therapies aimed at restoring normal insulin signaling in the CNS may have beneficial effects on brain function. Intranasal administration of insulin increases insulin signaling in the brain without raising peripheral levels and causing hypoglycemia. Insulin detemir is an insulin analogue that may have better action in brain than other insulin formulations because of its albumin binding properties. The investigators will test the therapeutic effects of intranasally-administered insulin detemir in a study in which participants will receive insulin detemir, regular insulin, or placebo over a four month period. The investigators will test the hypothesis that insulin and insulin detemir will both improve memory and daily functioning in persons with AD/aMCI compared with placebo, but that insulin detemir will have the greatest effect.

Condition Intervention Phase
Alzheimer's Disease
Mild Cognitive Impairment
Drug: saline
Drug: insulin detemir
Drug: Insulin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)

Resource links provided by NLM:

Further study details as provided by University of Washington:

Primary Outcome Measures:
  • Verbal Memory Composite [ Time Frame: Change from Baseline in Verbal Memory at 16 weeks ] [ Designated as safety issue: No ]
    The composite will consist of the weighted sum of Immediate + Delayed Story Recall and Immediate +Delayed List Recall

Secondary Outcome Measures:
  • Glucose Tolerance [ Time Frame: Change from Baseline in Glucose Tolerance at 16 Weeks ] [ Designated as safety issue: Yes ]
    Subjects will undergo oral glucose tolerance test (OGTT) to assess glucose tolerance

  • Cerebral Blood Flow [ Time Frame: Change from Baseline in Cerebral Blood Flow at 16 Weeks ] [ Designated as safety issue: No ]
    Functional MRI and arterial-spin labeling perfusion MRI

  • Cerebral Spinal Fluid (CSF) Biomarkers of AD [ Time Frame: Change from Baseline in CSF Biomarkers at 16 Weeks ] [ Designated as safety issue: No ]
    CSF Abeta (ABeta 38, ABeta 40, and Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject.

  • Plasma Biomarkers of AD [ Time Frame: Change from Baseline in Plasma Biomarkers at 16 Weeks ] [ Designated as safety issue: No ]
    Plasma Abeta (ABeta 38, ABeta 40, and Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject.

  • Neuropsychological Test of Executive Function 1 [ Time Frame: Change from Baseline in Executive Functioning at 16 Weeks ] [ Designated as safety issue: No ]
    Computerized Dot Counting Test (test of executive functioning)

  • Neuropsychological Test of Executive Functioning 2 [ Time Frame: Change from Baseline in Executive Functioning at 16 Weeks ] [ Designated as safety issue: No ]
    Computerized Stroop Test

  • Neuropsychological Tests of Visual Working Memory [ Time Frame: Change from Baseline in Visual Working Memory at 16 Weeks ] [ Designated as safety issue: No ]
    Benton Visual Retention Test Form F&G (a test of visual working memory)

  • Functional Ability [ Time Frame: Change from Baseline in Functional Ability at 16 Weeks ] [ Designated as safety issue: No ]
    Subjects will have a collateral informant (i.e., spouse or friend) rate the subjects' ability to carry out activities of daily living on the Dementia Severity Rating Scale.

  • The Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog/Alzheimer's Disease Cooperative Study (ADCS)] - MCI revision [ Time Frame: Change from Baseline in this measure at 16 Weeks ] [ Designated as safety issue: No ]
    This cognitive screening measure contains measures of confrontational naming, following commands, constructional praxis, ideational praxis, orientation, and language production and comprehension.

Estimated Enrollment: 90
Study Start Date: November 2011
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Saline Drug: saline
saline, administered intranasally twice per day for a 16 week duration
Other Name: saline solution
Experimental: Insulin Detemir
20IU of Insulin Detemir taken twice per day (40IU total per day)
Drug: insulin detemir
20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)
Other Name: Levemir
Experimental: Insulin
20IU Insulin, administered twice per day (40IU total per day)
Drug: Insulin
20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)
Other Name: Novolin R

  Show Detailed Description


Ages Eligible for Study:   50 Years to 89 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 50-89
  • Diagnosed with mild cognitive impairment, or mild/moderate AD

Exclusion Criteria:

  • Excessively high or low blood pressure, heart rate
  • Pre-existing diabetes not controlled by exercise/diet
  • Previous/current use of insulin
  • Significant elevations in lipids, liver enzymes
  • Menstrual period within the last 12 months
  • Significant neurological or medical disorder (other than AD)
  • Significant use of nasal decongestants
  • Current use of anti-psychotic, anti-convulsive, anxiolytic, glucocorticoids, or sedative medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01595646

United States, Washington
VA Puget Sound Health Care System - American Lake Division
Tacoma, Washington, United States, 98493
Sponsors and Collaborators
University of Washington
Alzheimer's Association
Principal Investigator: Suzanne Craft, PhD VA Puget Sound HCS/University of Washington School of Medicine
  More Information

No publications provided

Responsible Party: Suzanne Craft, Professor, University of Washington Identifier: NCT01595646     History of Changes
Other Study ID Numbers: 39885-A, ZEN-10-173646US
Study First Received: May 8, 2012
Last Updated: December 17, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by University of Washington:
intranasal insulin
Alzheimer's disease
mild cognitive impairment

Additional relevant MeSH terms:
Alzheimer Disease
Mild Cognitive Impairment
Brain Diseases
Central Nervous System Diseases
Cognition Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Insulin, Globin Zinc
Insulin, Long-Acting
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on February 27, 2015